Enterprise Value
495.1M
Cash
231.6M
Avg Qtr Burn
-18.45M
Short % of Float
11.53%
Insider Ownership
1.91%
Institutional Own.
97.60%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
RPT193 (CCR4 antagonist) Details Atopic dermatitis | Phase 2b Data readout | |
FLX475 (CCR4 antagonist) Details Solid tumor/s, Cancer | Phase 2 Data readout | |
RPT193 (CCR4 antagonist) Details Asthma, Lung disease | Phase 2a Data readout |